MAPT and tauopathy: As described below, these studies led to the identification of a diverse set of compounds and putative drug targets that affect tau inclusion formation in primary neurons, providing a valuable resource for further investigation of potential targets and small molecules that might ultimately lead to new drug discovery opportunities for the treatment of AD and related tauopathies.